Eli Lilly shares were on pace for a record closing high Tuesday after the drugmaker released data from a late-stage Crohn’s disease trial and struck a deal to develop new cancer-targeting medicines.
Eli Lilly’s stock on pace for record close as Crohn’s disease trial hits the mark
